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Summary
Personalised therapy of breast cancer is the optimal therapeutic approach to the 
patient, taking into consideration his personal characteristics, as well as clinical cha-
racteristics of the malignant deasease, involving pathohistological and molecular ab-
normalities of certain tumour. With the devolopment of molecular oncology methods, 
genetic profiling of each individual tumor is possible. Beside the major subtypes of 
breast carcinoma based on steroide receptors, Ki-67 proliferative index, and HER-2 re-
ceptors, numerous genetic subtypes of breast cancer have been found due to enormous 
genetic heterogeneity and instability of tumor cells. Some of genetic changes are con-
sidered as “driving” genes, resulting in dysregulations of crucial signalling transduction 
pathways involving in cell proliferation, angiogenesis, apoptosis, invasion or metastasis. 
Certain components of signalling transduction pathways can be targeted molecules of 
the so-called targeted biological therapy. Proper understanding of complexities of these 
dysregulated multiple intracellular signalling cascades in tumor cells is essential for the 
development of novel potential molecular therapeutic targets.
Keywords: breast cancer; signalling pathways; personalysed therapy. 
The normal cells, as well as the tumor cells have capability to respond 
to the numerous external stimuli such as growth factors, hormons or cyto-
kines. This complex processes comprise recognition on cellular mebrane by 
receptors, intracellular signalling transduction pathways, activation of nu-
merous transcription factors, and expression of different genes. This is the 
way of cellular response to microenviroment, as well as regulation of cellular 
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proliferation and differentiation [1]. In this complex multifacorial nets of si-
gnalling transduction pathways from cellular membrane to nucleus, the cru-
tial role have protein kynases, enzymes involved in methabolic pathways, 
protein phosphorilation, transport and activation, as well as in degradation 
of proteins. Changes in components of signalling transduction pathways 
can result in malignant cell transformation. In normal cells signalling tran-
sduction pathway is precisly regulated. In tumor cells, crucial molecules of 
this complex signaling transduction pathways can be changed by different 
mechanisms, envolving expression of some oncogenes, leading to abnormal 
signalling transduction pathways, inhibition of apoptosis, uncontrolled tu-
mor cells proliferation, angiogenesis, tumor invasion and metastazing [2]. 
Activation of some oncogenes (e.g. ErbB2, PI3K, Akt, Myc,), or loss of functi-
on of some tumor supressor genes (TP53, or PTEN), resulting in changes in 
signalling pathways sach as PI3K/Akt/mTOR, or raf/MEK/ERK are implica-
ted to be involved in carcinogenesis of breast cancer [3]. Certain components 
of signalling transduction pathways can be targeted molecules of so called 
targeted biological therapy. Understanding of complexities of these dysregu-
lated multiple intracellular signalling cascades in the tumor cells is essential 
for the developing of novel potential molecular therapeutic targets [4]. 
Personalized therapy of malignant deseases, including breast cancer is, 
according to the definition, optimal therapeutic approach to the patient, ta-
king into consideration his individual, personal characteristics (including ge-
netic), as well as clinical characteristics of the malignant deasease, involving 
pathohystological and molecular abnormalities of certain tumor. With the 
devolopment of molecular oncology methods, especially with DNA micro-
array analyses, genetic profiling of each individual tumor is possible. Two 
biggest international projects of systematic genomic analyses of tumor sam-
ples are currently ongoing: The Cancer Genome Atlas – NIH project in USA, 
and International Cancer Genomic Consortium in the rest of the world (3). 
With these molecular genetic analyses, numerous genetic changes in breast 
cancer have been found, some of them are considered as „driving“ genes, 
but the real role of some genetic changes in carcinogenesis remans to be de-
termined [5]. 
According to the recommendations of St. Gallen conference (St. Gallen 
International Expert Consensus on the Primary Therapy of Early Breast Can-
cer, 2013) it is obligatory to determine major subtypes of breast cancer on 
the basis of immunohystochemical analysis of estrogene and progesterone 
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receptors, HER-2 receptors and Ki-67 proliferation index on the tumor ti-
ssue samples [6]. The therapeutic basis for luminal A and luminal B subtypes 
of steroide receptor positive breast cancer is hormonal therapy, imunothe-
rapy shoulod be included in the treatment of HER 2 positive subtypes, whi-
le chemotherapy is still the basis for treatment triple negative („basal like“) 
subtypes of breast cancer. However,  molecular analyses of individual breast 
carcinoma tissues revealed that each of these subtypes can comprise futher 
new genetic subtypes of tumors which can deffer in prognosis and response 
to the therapy. According to numerous studes in the field of breast cancer, 
a great therapeutic problem in this desease is pronounced heterogeneity of 
tumor cells among apparently similar tumors, as well as diffent tumor clo-
nes in even one tumor. Tumor genom is very unstable, prone to numerous 
changes and mutations, even during therapy, which can lead to induction of 
different mecahisms of resistance and survival of mutated clones of tumor 
cells [3].
Hormonal therapy of steroid receptor positive breast cancer is one of the 
oldest and most succesful personalyzed therapeutic approach. With hor-
monal therapy steroide receptor expression on tumor cells is modulate or 
downregulate and/or hormone synthesis is blocked, resulting in decreased 
activation of estrogen signalling pathway. However, it has been shown that 
there is possibility of parallel activation of different signalling transduction 
pathways in breast cancer cells together with steroide receptor pathway (e.g. 
signalling pathways of EGFR, and PI3K/Akt/mTOR) which can be activated 
in resistance to hormonal therapy [7]. We block one signalling pathway with 
targeted therapy, but tumor cells activate different compensatory mechani-
sms and other numerous signalling pathways. This is the basis for therapeu-
tic concept of necessity of parallel blocking of different signalling pathways 
– such as hormonal therapy together with mTOR inhibition in breast cancer 
patients (e.g. BOLERO-2 clinical trial  of addition of mTOR inhibitor everoli-
mus to aromatase inhibitor exemestan in the treatment of hormone receptor 
pozitive advanced breast cancer patients) [8,9]. Immunotherapy is the main-
stain for the treatment of HER-2 pozitive breast cancer [10]. However, it has 
been shown that significant percent of HER-2 positive breast cancer does not 
respond to immunotherapy [11]. Different expression of TOPO2A enzyme 
in the group of HER 2 positive breast cancer could be one of the reasons of 
heterogeity. Tumors with mutation of HER-2, instead of HER-2 amplification 
could be another subgroup [12]. Second and third generations of anti-HER-2 
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therapies are in clinical studies, as well as so called „dual blocking“ of ErbB2 
pathway (e.g. anti HER2/neu receptor antibody together with tyrosine kina-
se inhibitors,  as well as different combinations of chemotherapy, HER-2 bloc-
king and blocking of some other signalling pathways by targeted agents [13]. 
A recent molecular anlyses of triple negative breast cancer (TNBC) revieled 
that different subgroups can be identified, defined by mesenchymal features, 
immune system-related genes, DNA damage response genes and activated 
androgen receptor signalling [14]. Potential novel therapeutic targets will be 
defined on the basis of this heterogeneity, like PARP inhibitors in deficiencies 
in the BRCA1 gene pathway [13]. 
In conclusion, we can say that reliable prognostic and predictive para-
metars for breast cancer, or biomarkers for identification of different tumor 
subpopulations are still widely needed [1,15]. A great progress on the way of 
personalisation in the therapy of breast cancer has been already achieved, 
but because of enormous genetic instability and heterogeneity, breast cancer 
is still largely unknown and the subject of numerous investigations. 
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Sažetak
Personalizirano liječenje raka dojke –
signalni putovi i ciljano liječenje raka dojke
Personalizirana terapija karcinoma dojke obuhvaća optimalni terapijski pristup,  uzi-
majući u obzir pacijentove osobne karakteristike, kao i kliničke karakteristike pojedine 
maligne bolesti, uključujući patohistološke i molekularne abnormalnosti svakog pojedi-
nog tumora. Razvojem metoda molekularne onkologije omogućeno je genetičko profi-
liranje svakog individualnog tumora. Pored osnovnih subtipova karcinoma dojke teme-
ljem ekspresije steroidnih receptora, HER-2 receptora i čimbenika proliferacije Ki-67, a 
zbog velike hetrogenosti i nestabilnosti genoma tumorskih stanica, nalaze se i brojni 
drugi subtipovi. Neke od tih genetičkih promjena smatraju se tzv. pokretačkim genima 
odgovornim za poremećenu regulaciju ključnih signalnih puteva u stanici uključenih 
u staničnu proliferaciju, angiogenezu, apoptozu, invaziju ili metastaziranje. Određene 
komponente signalnih puteva su ciljne molekule tzv. ciljane biološke terapije. Razumi-
jevanje kompleksnosti mehanizama ovih poremećenih prijenosa signala u tumorskim 
stanicama ključno je za razvoj novih potencijalnih meta ciljane biološke terapije karci-
noma dojke. 
Ključne riječi: karcinom dojke; prijenos signala u stanici; personalizirana terapija.
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